Nautilus Biotechnology(US:NAUT) Globenewswire·2026-02-24 13:00Core Insights - Nautilus Biotechnology, Inc. has launched the Voyager™ Platform, enabling the analysis of up to 10 billion intact proteins and proteoforms in a single run, enhancing next-generation proteomics across various research fields [3][4][5] Product Features - The Voyager Platform utilizes machine-learning powered analysis to identify and quantify intact protein molecules, featuring a user-friendly touchscreen interface and a benchtop design that does not require specialized lab facilities [4][5][13] - The platform's Iterative Mapping approach allows for rapid measurement of intact single-molecule proteins, accommodating a wide dynamic range and providing unique binding patterns for each molecule [5][13] Development and Testing - The Voyager Platform was successfully field-tested at the Buck Institute for Research on Aging, yielding novel insights into tau proteoform biology [4][10] - An Early Access Program was launched in January 2026, allowing researchers to utilize the platform's capabilities before its broader commercial availability expected in late 2026 [6][8] Applications and Impact - The initial offering of the Early Access Program includes the Nautilus Tau Proteoforms assay, which quantifies up to 768 full-length tau proteoform groups, critical for developing biomarkers and drug targets for neurodegenerative disorders like Alzheimer's disease [9][10] - The Voyager Platform aims to democratize access to proteomics, facilitating advancements in biomarker discovery, diagnostics, and therapeutic innovation [6][10] Future Presentations - Nautilus will present data on the Voyager Platform and its applications at the US HUPO 2026 conference, including sessions on tau proteoform analysis and large-scale proteoform detection capabilities [11][12]